These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2935368)

  • 21. Medroxyprogesterone acetate in human serum.
    Mathrubutham M; Fotherby K
    J Steroid Biochem; 1981 Aug; 14(8):783-6. PubMed ID: 6457936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prenatal toxicity of medroxyprogesterone acetate in rabbits, rats, and mice.
    Andrew FD; Staples RE
    Teratology; 1977 Feb; 15(1):25-32. PubMed ID: 841480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma levels of medroxyprogesterone acetate (MPA), estradiol and progesterone in the rhesus monkey after intramuscular adminstration of Depo-Provera.
    Mora G; Johansson ED
    Contraception; 1976 Sep; 14(3):343-50. PubMed ID: 824097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioimmunoassay for medroxyprogesterone acetate (Provera) using the 11alpha-hydroxy succinyl conjugate.
    Royer ME; Ko H; Campbell JA; Murray HC; Evans JS; Kaiser DG
    Steroids; 1974 May; 23(5):713-30. PubMed ID: 4365969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In utero exposure to steroid contraceptives and survival during infancy.
    Gray RH; Pardthaisong T
    Am J Epidemiol; 1991 Oct; 134(8):804-11. PubMed ID: 1835283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of breast cancer with medroxyprogesterone acetate.
    Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
    Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioavailability of medroxyprogesterone acetate from three oral dosage formulations.
    Stalker DJ; Welshman IR; Pollock SR
    Clin Ther; 1992; 14(4):544-52. PubMed ID: 1388093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In utero exposure to steroid contraceptives and outcome of pregnancy.
    Pardthaisong T; Gray RH
    Am J Epidemiol; 1991 Oct; 134(8):795-803. PubMed ID: 1835282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The bioavailability of an orally administered medroxyprogesterone acetate suspension.
    Antal EJ; Gillespie WR; Albert KS
    Int J Clin Pharmacol Ther Toxicol; 1983 May; 21(5):257-9. PubMed ID: 6222996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Depo-Provera--ethical issues in its testing and distribution.
    Potts M; Paxman JM
    J Med Ethics; 1984 Mar; 10(1):9-20. PubMed ID: 6231379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on the role of intestinal bacteria in metabolism of synthetic and natural steroid hormones.
    Adlercreutz H; Pulkkinen MO; Hämäläinen EK; Korpela JT
    J Steroid Biochem; 1984 Jan; 20(1):217-29. PubMed ID: 6231418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medroxyprogesterone acetate.
    IARC Monogr Eval Carcinog Risk Chem Hum; 1979 Dec; 21():417-29. PubMed ID: 120837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Some effects of depo-medroxyprogesterone acetate (DMPA): observations in the nursing infant and in the long-term user.
    Dahlberg K
    Int J Gynaecol Obstet; 1982 Feb; 20(1):43-8. PubMed ID: 6126406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medroxyprogesterone acetate in non-metastatic gestational trophoblastic disease.
    Goldberg GL; Cloete K; Bloch B; Wiswedel K; Altaras MM
    Br J Obstet Gynaecol; 1987 Jan; 94(1):22-5. PubMed ID: 2434125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma.
    Sall S; DiSaia P; Morrow CP; Mortel R; Prem K; Thigpen T; Creasman W
    Am J Obstet Gynecol; 1979 Nov; 135(5):647-50. PubMed ID: 507117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Forearm bone density in users of Depo-Provera as a contraceptive method.
    Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
    Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.
    Ortiz A; Hirol M; Stanczyk FZ; Goebelsmann U; Mishell DR
    J Clin Endocrinol Metab; 1977 Jan; 44(1):32-8. PubMed ID: 833262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The long-term growth and development of children exposed to Depo-Provera during pregnancy or lactation.
    Pardthaisong T; Yenchit C; Gray R
    Contraception; 1992 Apr; 45(4):313-24. PubMed ID: 1387602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
    Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
    Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular route.
    Løber J; Mouridsen HT; Salimtschik M; Johansson E
    Acta Obstet Gynecol Scand Suppl; 1981; 101():71-4. PubMed ID: 6946675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.